

Resource Summary Report

Generated by [dkNET](#) on Aug 20, 2026

HER3/ErbB3 (1B2E) Rabbit mAb

RRID:AB_10691324

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4754, RRID:AB_10691324

Antibody Information

URL: http://antibodyregistry.org/AB_10691324

Proper Citation: Cell Signaling Technology Cat# 4754, RRID:AB_10691324

Target Antigen: HER3 / ErbB3

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP. Consolidation on 11/2018: AB_10691324, AB_2099727.

Antibody Name: HER3/ErbB3 (1B2E) Rabbit mAb

Description: This monoclonal targets HER3 / ErbB3

Target Organism: rat, mouse, human

Clone ID: Clone 1B2E

Antibody ID: AB_10691324

Vendor: Cell Signaling Technology

Catalog Number: 4754

Record Creation Time: 20250820T040015+0000

Record Last Update: 20250820T174640+0000

Ratings and Alerts

No rating or validation information has been found for HER3/ErbB3 (1B2E) Rabbit mAb.

No alerts have been found for HER3/ErbB3 (1B2E) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. *Cancer discovery*, 16(1), 81.

Liu Y, et al. (2026) Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. *Oncogene*, 45(31), 3244.

Ma K, et al. (2026) ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging. *Cell*, 189(11), 3413.

Baro M, et al. (2025) Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. *Cell chemical biology*, 32(6), 839.

Gadal S, et al. (2025) Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. *Cancer research*, 85(9), 1611.

Wang H, et al. (2023) Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. *Cancer cell*, 41(7), 1345.

McLean JW, et al. (2022) Disruption of Endosomal Sorting in Schwann Cells Leads to Defective Myelination and Endosomal Abnormalities Observed in Charcot-Marie-Tooth Disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 42(25), 5085.

Mukherjee R, et al. (2021) Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. *Molecular cell*, 81(4), 708.

De Bacco F, et al. (2021) ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. *Cell reports*, 36(4), 109455.

Koga T, et al. (2021) Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study. *Translational lung cancer research*, 10(8), 3659.

Koivu MKA, et al. (2021) Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases. *Molecular cancer therapeutics*, 20(3), 564.

Zhang Z, et al. (2020) Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. *Cancer cell*, 38(2), 279.

Jard?? T, et al. (2020) Mesenchymal Niche-Derived Neuregulin-1 Drives Intestinal Stem Cell Proliferation and Regeneration of Damaged Epithelium. *Cell stem cell*, 27(4), 646.

Geuijen CAW, et al. (2018) Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade. *Cancer cell*, 33(5), 922.